Serine protease 58 (PRSS58)

Serine protease 58 (PRSS58) is a member of the trypsin family of serine proteases and is currently classified as a protein-coding gene, though it was previously described as a trypsinogen-like pseudogene[1][5][6][7]. It encodes a serine-type endopeptidase, playing a role in protein maturation, but its precise physiological substrate, tissue specificity, and clinical relevance remain poorly characterized[7]. PRSS58 and several related genes are localized to the T cell receptor beta locus on chromosome 7[1][6]. The gene has been associated with rare diseases such as dysplastic nevus syndrome and biliary dyskinesia[1]. There is currently no evidence that PRSS58 is a direct target for any approved drugs, nor are its clinical biomarker or safety implications established. Note: - There is confusion in nomenclature and major overlap with other trypsin-related serine proteases (e.g., PRSS1, TRY1, TRYX3). The name "Trypsin-X3" or overlap with PRSS1/TRY1 is misleading for this distinct gene, and these aliases should be used with caution[1][2][5][7]. - No established therapeutic targeting or validated small molecule/protein inhibitors/activators for PRSS58 currently exist in the literature or clinical practice[1][5][7]. - Any attempt to map this gene as "PRSS1" (the major pancreatic trypsinogen) or as a canonical therapeutic target is incorrect, hence is_incorrect: true due to the high potential for misidentification with established targets. Summary: Serine protease 58 (PRSS58) is a *rare, understudied serine protease* in the trypsin family, not a major validated drug or biomarker target, with significant ambiguity in its nomenclature and distinction from clinically established trypsins[1][5][7].

Other names

TRYX3Trypsin-X3trypsin X3UNQ2540/PRO6090serine protease 58protease, serine 58PRSS58